trending Market Intelligence /marketintelligence/en/news-insights/trending/nrjccwum0pg7ffqjk5odma2 content esgSubNav
In This List

Humanigen appoints chief medical officer

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Humanigen appoints chief medical officer

Brisbane, Calif.-based Humanigen Inc. named Tarek Sahmoud as its chief medical officer.

Sahmoud consults a number of chimeric antigen receptor T cell therapy companies on their clinical and regulatory plans.

He recently served as the chief medical officer for Eisai Co. Ltd.'s unit H3 Biomedicine Inc., a biopharmaceutical company engaged in the discovery and development of small-molecule drugs to treat cancer.

Humanigen is developing CAR-T optimization and cancer treatments.